{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T00:20:49Z","timestamp":1793319649135,"version":"4.5.0"},"reference-count":132,"publisher":"Oxford University Press (OUP)","issue":"2","license":[{"start":{"date-parts":[[2021,2,3]],"date-time":"2021-02-03T00:00:00Z","timestamp":1612310400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"funder":[{"DOI":"10.13039\/100000050","name":"National Heart, Lung, and Blood Institute","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000050","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["HL136962"],"award-info":[{"award-number":["HL136962"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2022,1,29]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Over the past four decades, no class of drugs has had more impact on cardiovascular health than the 3-hydroxy-methylglutaryl coenzyme A reductase inhibitors or statins. Developed as potent lipid-lowering agents, statins were later shown to reduce morbidity and mortality of patients who are at risk for cardiovascular disease. However, retrospective analyses of some of these clinical trials have uncovered some aspects of their clinical benefits that may be additional to their lipid-lowering effects. Such \u2018pleiotropic\u2019 effects of statins garnered intense interest and debate over its contribution to cardiovascular risk reduction. This review will provide a brief background of statin pleiotropy, assess the available clinical evidence for and against their non-lipid-lowering benefits, and propose future research directions in this field.<\/jats:p>","DOI":"10.1093\/cvr\/cvab032","type":"journal-article","created":{"date-parts":[[2021,2,3]],"date-time":"2021-02-03T02:53:14Z","timestamp":1612320794000},"page":"413-423","source":"Crossref","is-referenced-by-count":109,"title":["Emerging views of statin pleiotropy and cholesterol lowering"],"prefix":"10.1093","volume":"118","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7764-2728","authenticated-orcid":false,"given":"Dongbo","family":"Yu","sequence":"first","affiliation":[{"name":"Section of Cardiology, Department of Medicine, University of Chicago, Chicago, IL 60637, USA"},{"name":"Department of Cardiovascular Care, ThedaCare Regional Medical Center, Appleton, WI, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9679-4252","authenticated-orcid":false,"given":"James K","family":"Liao","sequence":"additional","affiliation":[{"name":"Section of Cardiology, Department of Medicine, University of Chicago, Chicago, IL 60637, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2021,2,3]]},"reference":[{"key":"2022013117274921900_cvab032-B1","doi-asserted-by":"crossref","first-page":"e67","DOI":"10.1161\/CIR.0000000000000558","article-title":"Heart Disease and Stroke Statistics-2018 Update: a Report From the American Heart Association","volume":"137","author":"Benjamin","year":"2018","journal-title":"Circulation"},{"key":"2022013117274921900_cvab032-B2","doi-asserted-by":"crossref","first-page":"1617","DOI":"10.1001\/jama.1971.03180230027005","article-title":"Premature mortality from coronary heart disease. The Framingham study","volume":"215","author":"Gordon","year":"1971","journal-title":"JAMA"},{"key":"2022013117274921900_cvab032-B3","doi-asserted-by":"crossref","first-page":"2823","DOI":"10.1001\/jama.1986.03380200061022","article-title":"Is relationship between serum cholesterol and risk of premature death from coronary heart disease continuous and graded? Findings in 356,222 primary screenees of the Multiple Risk Factor Intervention Trial (MRFIT)","volume":"256","author":"Stamler","year":"1986","journal-title":"JAMA"},{"key":"2022013117274921900_cvab032-B4","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1001\/jama.1995.03530020049031","article-title":"Serum total cholesterol and long-term coronary heart disease mortality in different cultures. Twenty-five-year follow-up of the seven countries study","volume":"274","author":"Verschuren","year":"1995","journal-title":"JAMA"},{"key":"2022013117274921900_cvab032-B5","doi-asserted-by":"crossref","first-page":"1346","DOI":"10.7164\/antibiotics.29.1346","article-title":"ML-236A, ML-236B, and ML-236C, new inhibitors of cholesterogenesis produced by Penicillium citrinium","volume":"29","author":"Endo","year":"1976","journal-title":"J Antibiot"},{"key":"2022013117274921900_cvab032-B6","doi-asserted-by":"crossref","first-page":"3957","DOI":"10.1073\/pnas.77.7.3957","article-title":"Mevinolin: a highly potent competitive inhibitor of hydroxymethylglutaryl-coenzyme A reductase and a cholesterol-lowering agent","volume":"77","author":"Alberts","year":"1980","journal-title":"Proc Natl Acad Sci USA"},{"key":"2022013117274921900_cvab032-B7","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/j.phrs.2014.03.002","article-title":"The pharmacology of statins","volume":"88","author":"Sirtori","year":"2014","journal-title":"Pharmacol Res"},{"key":"2022013117274921900_cvab032-B8","doi-asserted-by":"crossref","first-page":"1160","DOI":"10.1126\/science.1059344","article-title":"Structural mechanism for statin inhibition of HMG-CoA reductase","volume":"292","author":"Istvan","year":"2001","journal-title":"Science"},{"key":"2022013117274921900_cvab032-B9","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1016\/0163-7258(85)90025-7","article-title":"Drugs inhibiting HMG-CoA reductase","volume":"31","author":"Endo","year":"1985","journal-title":"Pharmacol Ther"},{"key":"2022013117274921900_cvab032-B10","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1056\/NEJM199908053410604","article-title":"Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterol. Veterans Affairs High-Density Lipoprotein Cholesterol Intervention Trial Study Group","volume":"341","author":"Rubins","year":"1999","journal-title":"N Engl J Med"},{"key":"2022013117274921900_cvab032-B11","doi-asserted-by":"crossref","first-page":"1245","DOI":"10.1016\/S0735-1097(86)80293-5","article-title":"Fifteen year mortality in Coronary Drug Project patients: long-term benefit with niacin","volume":"8","author":"Canner","year":"1986","journal-title":"J Am Coll Cardiol"},{"key":"2022013117274921900_cvab032-B12","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1001\/jama.1984.03340270029025","article-title":"I. Reduction in incidence of coronary heart disease","volume":"251","year":"1984","journal-title":"JAMA"},{"key":"2022013117274921900_cvab032-B13","doi-asserted-by":"crossref","first-page":"1615","DOI":"10.1001\/jama.279.20.1615","article-title":"Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS\/TexCAPS. Air Force\/Texas Coronary Atherosclerosis Prevention Study","volume":"279","author":"Downs","year":"1998","journal-title":"JAMA"},{"key":"2022013117274921900_cvab032-B14","doi-asserted-by":"crossref","first-page":"1301","DOI":"10.1056\/NEJM199511163332001","article-title":"Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. West of Scotland Coronary Prevention Study Group","volume":"333","author":"Shepherd","year":"1995","journal-title":"N Engl J Med"},{"key":"2022013117274921900_cvab032-B15","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1016\/S0140-6736(02)09327-3","article-title":"MRC\/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial","volume":"360","year":"2002","journal-title":"Lancet"},{"key":"2022013117274921900_cvab032-B16","doi-asserted-by":"crossref","first-page":"1425","DOI":"10.1056\/NEJMoa050461","article-title":"Treating to New Targets I. Intensive lipid lowering with atorvastatin in patients with stable coronary disease","volume":"352","author":"LaRosa","year":"2005","journal-title":"N Engl J Med"},{"key":"2022013117274921900_cvab032-B17","first-page":"1383","article-title":"Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S)","volume":"344","year":"1994","journal-title":"Lancet"},{"key":"2022013117274921900_cvab032-B18","doi-asserted-by":"crossref","first-page":"1001","DOI":"10.1056\/NEJM199610033351401","article-title":"The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events Trial investigators","volume":"335","author":"Sacks","year":"1996","journal-title":"N Engl J Med"},{"key":"2022013117274921900_cvab032-B19","doi-asserted-by":"crossref","first-page":"1349","DOI":"10.1056\/NEJM199811053391902","article-title":"Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels","volume":"339","year":"1998","journal-title":"N Engl J Med"},{"key":"2022013117274921900_cvab032-B20","doi-asserted-by":"crossref","first-page":"1495","DOI":"10.1056\/NEJMoa040583","article-title":"Pravastatin or atorvastatin E, infection therapy-thrombolysis in myocardial infarction I. Intensive versus moderate lipid lowering with statins after acute coronary syndromes","volume":"350","author":"Cannon","year":"2004","journal-title":"N Engl J Med"},{"key":"2022013117274921900_cvab032-B21","doi-asserted-by":"crossref","first-page":"1711","DOI":"10.1001\/jama.285.13.1711","article-title":"Myocardial ischemia reduction with aggressive cholesterol lowering study I. Effects of atorvastatin on early recurrent ischemic events in acute coronary syndromes: the MIRACL study: a randomized controlled trial","volume":"285","author":"Schwartz","year":"2001","journal-title":"JAMA"},{"key":"2022013117274921900_cvab032-B22","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1161\/01.STR.0000057812.51734.FF","article-title":"Atherosclerosis risk in communities S. Plasma lipid profile and incident ischemic stroke: the Atherosclerosis Risk in Communities (ARIC) study","volume":"34","author":"Shahar","year":"2003","journal-title":"Stroke"},{"key":"2022013117274921900_cvab032-B23","doi-asserted-by":"crossref","first-page":"i19","DOI":"10.1136\/jech.56.suppl_1.i19","article-title":"Total and HDL cholesterol and risk of stroke. EUROSTROKE: a collaborative study among research centres in Europe","volume":"56","author":"Bots","year":"2002","journal-title":"J Epidemiol Community Health"},{"key":"2022013117274921900_cvab032-B24","doi-asserted-by":"crossref","first-page":"2535","DOI":"10.1161\/01.STR.30.12.2535","article-title":"Different risk factors for different stroke subtypes: association of blood pressure, cholesterol, and antioxidants","volume":"30","author":"Lepp\u00e4L\u00e4","year":"1999","journal-title":"Stroke"},{"key":"2022013117274921900_cvab032-B25","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1056\/NEJMoa061894","article-title":"Stroke prevention by aggressive reduction in cholesterol levels I. High-dose atorvastatin after stroke or transient ischemic attack","volume":"355","author":"Amarenco","year":"2006","journal-title":"N Engl J Med"},{"key":"2022013117274921900_cvab032-B26","doi-asserted-by":"crossref","first-page":"1071","DOI":"10.1001\/jama.291.9.1071","article-title":"Effect of intensive compared with moderate lipid-lowering therapy on progression of coronary atherosclerosis: a randomized controlled trial","volume":"291","author":"Nissen","year":"2004","journal-title":"JAMA"},{"key":"2022013117274921900_cvab032-B27","doi-asserted-by":"crossref","first-page":"1556","DOI":"10.1001\/jama.295.13.jpc60002","article-title":"Effect of very high-intensity statin therapy on regression of coronary atherosclerosis: the ASTEROID trial","volume":"295","author":"Nissen","year":"2006","journal-title":"JAMA"},{"key":"2022013117274921900_cvab032-B28","doi-asserted-by":"crossref","first-page":"2078","DOI":"10.1056\/NEJMoa1110874","article-title":"Effect of two intensive statin regimens on progression of coronary disease","volume":"365","author":"Nicholls","year":"2011","journal-title":"N Engl J Med"},{"key":"2022013117274921900_cvab032-B29","doi-asserted-by":"crossref","first-page":"2207","DOI":"10.1016\/j.jacc.2014.08.045","article-title":"Effect of atorvastatin therapy on fibrous cap thickness in coronary atherosclerotic plaque as assessed by optical coherence tomography: the EASY-FIT study","volume":"64","author":"Komukai","year":"2014","journal-title":"J Am Coll Cardiol"},{"key":"2022013117274921900_cvab032-B30","doi-asserted-by":"crossref","first-page":"1475","DOI":"10.1016\/j.jcmg.2018.04.015","article-title":"Effects of statins on coronary atherosclerotic plaques: the PARADIGM Study","volume":"11","author":"Lee","year":"2018","journal-title":"JACC Cardiovasc Imag"},{"key":"2022013117274921900_cvab032-B31","doi-asserted-by":"crossref","first-page":"993","DOI":"10.1161\/01.CIR.103.7.993","article-title":"Statins alter smooth muscle cell accumulation and collagen content in established atheroma of watanabe heritable hyperlipidemic rabbits","volume":"103","author":"Fukumoto","year":"2001","journal-title":"Circulation"},{"key":"2022013117274921900_cvab032-B32","doi-asserted-by":"crossref","first-page":"714","DOI":"10.1161\/ATVBAHA.119.313832","article-title":"Statins disrupt macrophage rac1 regulation leading to increased atherosclerotic plaque calcification","volume":"40","author":"Healy","year":"2020","journal-title":"ATVB"},{"key":"2022013117274921900_cvab032-B33","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1161\/01.CIR.103.2.276","article-title":"An HMG-CoA reductase inhibitor, cerivastatin, suppresses growth of macrophages expressing matrix metalloproteinases and tissue factor in vivo and in vitro","volume":"103","author":"Aikawa","year":"2001","journal-title":"Circulation"},{"key":"2022013117274921900_cvab032-B34","doi-asserted-by":"crossref","first-page":"926","DOI":"10.1161\/01.CIR.103.7.926","article-title":"Pravastatin treatment increases collagen content and decreases lipid content, inflammation, metalloproteinases, and cell death in human carotid plaques: implications for plaque stabilization","volume":"103","author":"Crisby","year":"2001","journal-title":"Circulation"},{"key":"2022013117274921900_cvab032-B35","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1016\/j.tcm.2019.01.001","article-title":"Effect of statins on atherosclerotic plaque","volume":"29","author":"Almeida","year":"2019","journal-title":"Trends Cardiovasc Med"},{"key":"2022013117274921900_cvab032-B36","doi-asserted-by":"crossref","first-page":"456","DOI":"10.1016\/j.tcm.2019.02.001","article-title":"Editorial commentary: the pleiotropic effect of statins on the atherosclerotic plaque and coronary heart disease","volume":"29","author":"Sakellarios","year":"2019","journal-title":"Trends Cardiovasc Med"},{"key":"2022013117274921900_cvab032-B37","first-page":"3","article-title":"What have we learned about the biology of atherosclerosis? The role of inflammation","volume":"88","author":"Libby","year":"2001","journal-title":"Am J Cardiol"},{"key":"2022013117274921900_cvab032-B38","doi-asserted-by":"crossref","first-page":"1557","DOI":"10.1056\/NEJMoa021993","article-title":"Comparison of C-reactive protein and low-density lipoprotein cholesterol levels in the prediction of first cardiovascular events","volume":"347","author":"Ridker","year":"2002","journal-title":"N Engl J Med"},{"key":"2022013117274921900_cvab032-B39","doi-asserted-by":"crossref","first-page":"2599","DOI":"10.1056\/NEJMoa040967","article-title":"Inflammatory markers and the risk of coronary heart disease in men and women","volume":"351","author":"Pai","year":"2004","journal-title":"N Engl J Med"},{"key":"2022013117274921900_cvab032-B40","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1001\/jama.286.1.64","article-title":"Effect of statin therapy on C-reactive protein levels: the pravastatin inflammation\/CRP evaluation (PRINCE): a randomized trial and cohort study","volume":"286","author":"Albert","year":"2001","journal-title":"JAMA"},{"key":"2022013117274921900_cvab032-B41","doi-asserted-by":"crossref","first-page":"1560","DOI":"10.1161\/01.CIR.0000091404.09558.AF","article-title":"Myocardial ischemia reduction with aggressive cholesterol lowering study I. High-dose atorvastatin enhances the decline in inflammatory markers in patients with acute coronary syndromes in the MIRACL study","volume":"108","author":"Kinlay","year":"2003","journal-title":"Circulation"},{"key":"2022013117274921900_cvab032-B42","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1161\/01.CIR.100.3.230","article-title":"Long-term effects of pravastatin on plasma concentration of C-reactive protein. The Cholesterol and Recurrent Events (CARE) Investigators","volume":"100","author":"Ridker","year":"1999","journal-title":"Circulation"},{"key":"2022013117274921900_cvab032-B43","doi-asserted-by":"crossref","first-page":"2195","DOI":"10.1056\/NEJMoa0807646","article-title":"Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein","volume":"359","author":"Ridker","year":"2008","journal-title":"N Engl J Med"},{"key":"2022013117274921900_cvab032-B44","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1161\/CIRCRESAHA.116.308537","article-title":"Pleiotropic effects of statins on the cardiovascular system","volume":"120","author":"Oesterle","year":"2017","journal-title":"Circ Res"},{"key":"2022013117274921900_cvab032-B45","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1161\/01.ATV.0000043456.48735.20","article-title":"HMG-CoA reductase inhibitors regulate inflammatory transcription factors in human endothelial and vascular smooth muscle cells","volume":"23","author":"Dichtl","year":"2003","journal-title":"ATVB"},{"key":"2022013117274921900_cvab032-B46","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1093\/intimm\/dxp037","article-title":"Protein geranylgeranylation regulates the balance between Th17 cells and Foxp3+ regulatory T cells","volume":"21","author":"Kagami","year":"2009","journal-title":"Int Immunol"},{"key":"2022013117274921900_cvab032-B47","doi-asserted-by":"crossref","first-page":"4219","DOI":"10.1161\/01.CIR.96.12.4219","article-title":"Circulating adhesion molecules VCAM-1, ICAM-1, and E-selectin in carotid atherosclerosis and incident coronary heart disease cases: the Atherosclerosis Risk In Communities (ARIC) study","volume":"96","author":"Hwang","year":"1997","journal-title":"Circulation"},{"key":"2022013117274921900_cvab032-B48","doi-asserted-by":"crossref","first-page":"2067","DOI":"10.1242\/jcs.02340","article-title":"PECAM-1, alpha6 integrins and neutrophil elastase cooperate in mediating neutrophil transmigration","volume":"118","author":"Wang","year":"2005","journal-title":"J Cell Sci"},{"key":"2022013117274921900_cvab032-B49","doi-asserted-by":"crossref","first-page":"2497","DOI":"10.1056\/NEJMoa1912388","article-title":"Efficacy and safety of low-dose colchicine after myocardial infarction","volume":"381","author":"Tardif","year":"2019","journal-title":"N Engl J Med"},{"key":"2022013117274921900_cvab032-B50","doi-asserted-by":"crossref","first-page":"752","DOI":"10.1056\/NEJMoa1809798","article-title":"Low-dose methotrexate for the prevention of atherosclerotic events","volume":"380","author":"Ridker","year":"2019","journal-title":"N Engl J Med"},{"key":"2022013117274921900_cvab032-B51","doi-asserted-by":"crossref","first-page":"d548","DOI":"10.1136\/bmj.d548","article-title":"Association between C reactive protein and coronary heart disease: Mendelian randomisation analysis based on individual participant data","volume":"342","author":"Wensley","year":"2011","journal-title":"BMJ"},{"key":"2022013117274921900_cvab032-B52","doi-asserted-by":"crossref","first-page":"3973","DOI":"10.1111\/bph.13805","article-title":"Vascular inflammation and low-density lipoproteins: is cholesterol the link? A lesson from the clinical trials","volume":"174","author":"Catapano","year":"2017","journal-title":"Br J Pharmacol"},{"key":"2022013117274921900_cvab032-B53","doi-asserted-by":"crossref","first-page":"e012428","DOI":"10.1161\/JAHA.119.012428","article-title":"Association between baseline, achieved, and reduction of CRP and cardiovascular outcomes after LDL cholesterol lowering with statins or ezetimibe: a systematic review and meta-analysis","volume":"8","author":"Zhang","year":"2019","journal-title":"J Am Heart Assoc"},{"key":"2022013117274921900_cvab032-B54","volume-title":"The Role of Lipids and Lipoproteins in Atherosclerosis","author":"Linton","year":"2019"},{"key":"2022013117274921900_cvab032-B55","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1172\/JCI0216421","article-title":"Isoprenoids as mediators of the biological effects of statins","volume":"110","author":"Liao","year":"2002","journal-title":"J Clin Invest"},{"key":"2022013117274921900_cvab032-B56","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1016\/j.cardiores.2005.07.002","article-title":"Statins prevent pulsatile stretch-induced proliferation of human saphenous vein smooth muscle cells via inhibition of Rho\/Rho-kinase pathway","volume":"68","author":"Kozai","year":"2005","journal-title":"Cardiovasc Res"},{"key":"2022013117274921900_cvab032-B57","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1016\/j.jvs.2005.05.041","article-title":"Hydrophilic statin suppresses vein graft intimal hyperplasia via endothelial cell-tropic Rho-kinase inhibition","volume":"42","author":"Yamanouchi","year":"2005","journal-title":"J Vasc Surg"},{"key":"2022013117274921900_cvab032-B58","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1016\/j.amjcard.2008.10.008","article-title":"Comparison of effects of rosuvastatin (10 mg) versus atorvastatin (40 mg) on rho kinase activity in Caucasian men with a previous atherosclerotic event","volume":"103","author":"Rawlings","year":"2009","journal-title":"Am J Cardiol"},{"key":"2022013117274921900_cvab032-B59","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1016\/j.atherosclerosis.2008.12.023","article-title":"Statins inhibit Rho kinase activity in patients with atherosclerosis","volume":"205","author":"Nohria","year":"2009","journal-title":"Atherosclerosis"},{"key":"2022013117274921900_cvab032-B60","doi-asserted-by":"crossref","first-page":"576","DOI":"10.1097\/FJC.0b013e318250ba2c","article-title":"Simvastatin attenuated cerebrovascular cell proliferation in the development of hypertension through Rho\/Rho-kinase pathway","volume":"59","author":"Ma","year":"2012","journal-title":"J Cardiovasc Pharmacol"},{"key":"2022013117274921900_cvab032-B61","doi-asserted-by":"crossref","first-page":"17747","DOI":"10.1038\/s41598-019-53700-6","article-title":"Statin-specific inhibition of Rab-GTPase regulates cPKC-mediated IKs internalization","volume":"9","author":"Ronzier","year":"2019","journal-title":"Sci Rep"},{"key":"2022013117274921900_cvab032-B62","doi-asserted-by":"crossref","first-page":"1129","DOI":"10.1161\/01.CIR.97.12.1129","article-title":"Upregulation of endothelial nitric oxide synthase by HMG CoA reductase inhibitors","volume":"97","author":"Laufs","year":"1998","journal-title":"Circulation"},{"key":"2022013117274921900_cvab032-B63","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1111\/fcp.12173","article-title":"Atorvastatin acutely reduces the reactivity to spasmogens in rat aorta: implication of the inhibition of geranylgeranylation and MYPT-1 phosphorylation","volume":"30","author":"Yildirim","year":"2016","journal-title":"Fundam Clin Pharmacol"},{"key":"2022013117274921900_cvab032-B64","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1189\/jlb.3A0916-388RR","article-title":"TNF induces neutrophil adhesion via formin-dependent cytoskeletal reorganization and activation of beta-integrin function","volume":"103","author":"Silveira","year":"2018","journal-title":"J Leukoc Biol"},{"key":"2022013117274921900_cvab032-B65","doi-asserted-by":"crossref","first-page":"2885","DOI":"10.1161\/hc2401.092816","article-title":"Increase in circulating endothelial progenitor cells by statin therapy in patients with stable coronary artery disease","volume":"103","author":"Vasa","year":"2001","journal-title":"Circulation"},{"key":"2022013117274921900_cvab032-B66","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1172\/JCI200113131","article-title":"HMG-CoA reductase inhibitor mobilizes bone marrow-derived endothelial progenitor cells","volume":"108","author":"Llevadot","year":"2001","journal-title":"J Clin Invest"},{"key":"2022013117274921900_cvab032-B67","doi-asserted-by":"crossref","first-page":"3017","DOI":"10.1161\/01.CIR.0000018166.84319.55","article-title":"Statin therapy accelerates reendothelialization: a novel effect involving mobilization and incorporation of bone marrow-derived endothelial progenitor cells","volume":"105","author":"Walter","year":"2002","journal-title":"Circulation"},{"key":"2022013117274921900_cvab032-B68","doi-asserted-by":"crossref","first-page":"3628","DOI":"10.1073\/pnas.88.9.3628","article-title":"Cell cycle-specific effects of lovastatin","volume":"88","author":"Jakobisiak","year":"1991","journal-title":"Proc Natl Acad Sci USA"},{"key":"2022013117274921900_cvab032-B69","doi-asserted-by":"crossref","first-page":"21926","DOI":"10.1074\/jbc.274.31.21926","article-title":"3-Hydroxy-3-methylglutaryl-CoA reductase inhibitors attenuate vascular smooth muscle proliferation by preventing rho GTPase-induced down-regulation of p27(Kip1)","volume":"274","author":"Laufs","year":"1999","journal-title":"J Biol Chem"},{"key":"2022013117274921900_cvab032-B70","doi-asserted-by":"crossref","first-page":"8123","DOI":"10.3892\/mmr.2017.7640","article-title":"Simvastatin attenuated rat thoracic aorta remodeling by decreasing ROCK2mediated CyPA secretion and CD147ERK1\/2cyclin pathway","volume":"16","author":"Tang","year":"2017","journal-title":"Mol Med Rep"},{"key":"2022013117274921900_cvab032-B71","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1016\/S0049-3848(99)00037-7","article-title":"Reduction of platelet activity markers in type II hypercholesterolemic patients by a HMG-CoA-reductase inhibitor","volume":"95","author":"Huhle","year":"1999","journal-title":"Thromb Res"},{"key":"2022013117274921900_cvab032-B72","doi-asserted-by":"crossref","first-page":"115","DOI":"10.5114\/aoms.2015.49216","article-title":"The influence of statin therapy on platelet activity markers in hyperlipidemic patients after ischemic stroke","volume":"1","author":"Pawelczyk","year":"2015","journal-title":"aoms"},{"key":"2022013117274921900_cvab032-B73","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1161\/01.ATV.15.2.247","article-title":"Inhibition of thromboxane biosynthesis and platelet function by simvastatin in type IIa hypercholesterolemia","volume":"15","author":"Notarbartolo","year":"1995","journal-title":"ATVB"},{"key":"2022013117274921900_cvab032-B74","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1016\/j.atherosclerosis.2010.10.006","article-title":"Effects of atorvastatin and rosuvastatin on thromboxane-dependent platelet activation and oxidative stress in hypercholesterolemia","volume":"214","author":"Puccetti","year":"2011","journal-title":"Atherosclerosis"},{"key":"2022013117274921900_cvab032-B75","doi-asserted-by":"crossref","first-page":"759","DOI":"10.1161\/01.ATV.15.6.759","article-title":"Platelet cytosolic Ca2+ and membrane dynamics in patients with primary hypercholesterolemia. Effects of pravastatin","volume":"15","author":"Le Quan Sang","year":"1995","journal-title":"ATVB"},{"key":"2022013117274921900_cvab032-B76","doi-asserted-by":"crossref","first-page":"3188","DOI":"10.1182\/blood-2013-04-491845","article-title":"Antithrombotic actions of statins involve PECAM-1 signaling","volume":"122","author":"Moraes","year":"2013","journal-title":"Blood"},{"key":"2022013117274921900_cvab032-B77","doi-asserted-by":"crossref","first-page":"706","DOI":"10.1161\/ATVBAHA.108.183160","article-title":"Antiplatelet actions of statins and fibrates are mediated by PPARs","volume":"29","author":"Ali","year":"2009","journal-title":"ATVB"},{"key":"2022013117274921900_cvab032-B78","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1016\/j.thromres.2014.05.005","article-title":"Effects of peroxisome proliferator-activated receptor gamma in simvastatin antiplatelet activity: influences on cAMP and mitogen-activated protein kinases","volume":"134","author":"Du","year":"2014","journal-title":"Thromb Res"},{"key":"2022013117274921900_cvab032-B79","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1161\/01.CIR.0000022843.76104.01","article-title":"Simvastatin reduces neointimal thickening in low-density lipoprotein receptor-deficient mice after experimental angioplasty without changing plasma lipids","volume":"106","author":"Chen","year":"2002","journal-title":"Circulation"},{"key":"2022013117274921900_cvab032-B80","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.jss.2016.10.007","article-title":"Fluvastatin inhibits intimal hyperplasia in wild-type but not Thbs1-null mice","volume":"210","author":"Desai","year":"2017","journal-title":"J Surg Res"},{"key":"2022013117274921900_cvab032-B81","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1056\/NEJM199509073331003","article-title":"Effect of pravastatin on outcomes after cardiac transplantation","volume":"333","author":"Kobashigawa","year":"1995","journal-title":"N Engl J Med"},{"key":"2022013117274921900_cvab032-B82","doi-asserted-by":"crossref","first-page":"2324","DOI":"10.1007\/s00268-014-2543-x","article-title":"Graft vessel disease following heart transplantation: a systematic review of the role of statin therapy","volume":"38","author":"Som","year":"2014","journal-title":"World J Surg"},{"key":"2022013117274921900_cvab032-B83","doi-asserted-by":"crossref","first-page":"2387","DOI":"10.1056\/NEJMoa1410489","article-title":"Ezetimibe added to statin therapy after acute coronary syndromes","volume":"372","author":"Cannon","year":"2015","journal-title":"N Engl J Med"},{"key":"2022013117274921900_cvab032-B84","doi-asserted-by":"crossref","first-page":"1527","DOI":"10.1056\/NEJMoa1701488","article-title":"Cardiovascular efficacy and safety of bococizumab in high-risk patients","volume":"376","author":"Ridker","year":"2017","journal-title":"N Engl J Med"},{"key":"2022013117274921900_cvab032-B85","doi-asserted-by":"crossref","first-page":"1713","DOI":"10.1056\/NEJMoa1615664","article-title":"Evolocumab and clinical outcomes in patients with cardiovascular disease","volume":"376","author":"Sabatine","year":"2017","journal-title":"N Engl J Med"},{"key":"2022013117274921900_cvab032-B86","doi-asserted-by":"crossref","first-page":"2097","DOI":"10.1056\/NEJMoa1801174","article-title":"Alirocumab and cardiovascular outcomes after acute coronary syndrome","volume":"379","author":"Schwartz","year":"2018","journal-title":"N Engl J Med"},{"key":"2022013117274921900_cvab032-B87","doi-asserted-by":"crossref","first-page":"2373","DOI":"10.1001\/jama.2016.16951","article-title":"Effect of evolocumab on progression of coronary disease in statin-treated patients: the GLAGOV Randomized Clinical Trial","volume":"316","author":"Nicholls","year":"2016","journal-title":"JAMA"},{"key":"2022013117274921900_cvab032-B88","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1016\/j.amjmed.2019.06.029","article-title":"Cholesterol lowering and stroke: no longer room for pleiotropic effects of statins\u2014confirmation from PCSK9 inhibitor studies","volume":"133","author":"Salvatore","year":"2020","journal-title":"Am J Med"},{"key":"2022013117274921900_cvab032-B89","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1161\/ATVBAHA.117.310052","article-title":"Evaluation of the pleiotropic effects of statins: a reanalysis of the randomized trial evidence using egger regression-brief report","volume":"38","author":"Labos","year":"2018","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"2022013117274921900_cvab032-B90","doi-asserted-by":"crossref","first-page":"820","DOI":"10.1161\/STROKEAHA.117.019653","article-title":"Role of blood lipids in the development of ischemic stroke and its subtypes: a Mendelian Randomization Study","volume":"49","author":"Hindy","year":"2018","journal-title":"Stroke"},{"key":"2022013117274921900_cvab032-B91","doi-asserted-by":"crossref","first-page":"1851","DOI":"10.1056\/NEJMoa0900241","article-title":"A randomized trial of rosuvastatin in the prevention of venous thromboembolism","volume":"360","author":"Glynn","year":"2009","journal-title":"N Engl J Med"},{"key":"2022013117274921900_cvab032-B92","doi-asserted-by":"crossref","first-page":"1600","DOI":"10.1161\/CIRCULATIONAHA.120.046397","article-title":"The Effect of PCSK9 (proprotein convertase subtilisin\/Kexin Type 9) inhibition on the risk of venous thromboembolism","volume":"141","author":"Marston","year":"2020","journal-title":"Circulation"},{"key":"2022013117274921900_cvab032-B93","doi-asserted-by":"crossref","first-page":"2675","DOI":"10.1182\/blood-2008-05-157412","article-title":"High-density lipoprotein cholesterol and venous thromboembolism in the Longitudinal Investigation of Thromboembolism Etiology (LITE)","volume":"112","author":"Chamberlain","year":"2008","journal-title":"Blood"},{"key":"2022013117274921900_cvab032-B94","doi-asserted-by":"crossref","first-page":"923","DOI":"10.1160\/TH12-06-0426","article-title":"Lipid levels do not influence the risk of venous thromboembolism. Results of a population-based cohort study","volume":"108","author":"van Schouwenburg","year":"2012","journal-title":"Thromb Haemost"},{"key":"2022013117274921900_cvab032-B95","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1007\/s10654-017-0251-1","article-title":"Lipid levels and risk of venous thrombosis: results from the MEGA-study","volume":"32","author":"Morelli","year":"2017","journal-title":"Eur J Epidemiol"},{"key":"2022013117274921900_cvab032-B96","doi-asserted-by":"crossref","first-page":"588","DOI":"10.1111\/j.1538-7836.2009.03302.x","article-title":"Lipid biomarkers, hormone therapy and the risk of venous thromboembolism in women","volume":"7","author":"Everett","year":"2009","journal-title":"J Thromb Haemost"},{"key":"2022013117274921900_cvab032-B97","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1161\/CIRCULATIONAHA.118.034032","article-title":"Inflammatory and cholesterol risk in the FOURIER Trial","volume":"138","author":"Bohula","year":"2018","journal-title":"Circulation"},{"key":"2022013117274921900_cvab032-B98","doi-asserted-by":"crossref","first-page":"e022348","DOI":"10.1136\/bmjopen-2018-022348","article-title":"Impact of PCSK9 monoclonal antibodies on circulating hs-CRP levels: a systematic review and meta-analysis of randomised controlled trials","volume":"8","author":"Cao","year":"2018","journal-title":"BMJ Open"},{"key":"2022013117274921900_cvab032-B99","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1016\/j.jacc.2019.10.057","article-title":"Effect of alirocumab on lipoprotein(a) and cardiovascular risk after acute coronary syndrome","volume":"75","author":"Bittner","year":"2020","journal-title":"J Am Coll Cardiol"},{"key":"2022013117274921900_cvab032-B100","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1161\/CIRCULATIONAHA.113.004406","article-title":"Lipoprotein(a) concentrations, rosuvastatin therapy, and residual vascular risk: an analysis from the JUPITER Trial (Justification for the Use of Statins in Prevention: an Intervention Trial Evaluating Rosuvastatin)","volume":"129","author":"Khera","year":"2014","journal-title":"Circulation"},{"key":"2022013117274921900_cvab032-B101","doi-asserted-by":"crossref","first-page":"819","DOI":"10.1016\/j.it.2016.09.001","article-title":"The intracellular cholesterol landscape: dynamic integrator of the immune response","volume":"37","author":"Fessler","year":"2016","journal-title":"Trends Immunol"},{"key":"2022013117274921900_cvab032-B102","doi-asserted-by":"crossref","first-page":"1430","DOI":"10.1056\/NEJMoa1615758","article-title":"Inclisiran in patients at high cardiovascular risk with elevated LDL cholesterol","volume":"376","author":"Ray","year":"2017","journal-title":"N Engl J Med"},{"key":"2022013117274921900_cvab032-B103","doi-asserted-by":"crossref","first-page":"e011662","DOI":"10.1161\/JAHA.118.011662","article-title":"Efficacy and safety of bempedoic acid in patients with hypercholesterolemia and statin intolerance","volume":"8","author":"Laufs","year":"2019","journal-title":"J Am Heart Assoc"},{"key":"2022013117274921900_cvab032-B104","doi-asserted-by":"crossref","first-page":"1769","DOI":"10.1001\/jama.2019.16598","article-title":"Bempedoic acid for lowering LDL cholesterol","volume":"322","author":"Honigberg","year":"2019","journal-title":"JAMA"},{"key":"2022013117274921900_cvab032-B105","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1111\/imm.12902","article-title":"Immune modulatory effects of statins","volume":"154","author":"Zeiser","year":"2018","journal-title":"Immunology"},{"key":"2022013117274921900_cvab032-B106","first-page":"69","article-title":"The impact of statins therapy on disease activity and inflammatory factor in patients with rheumatoid arthritis: a meta-analysis","volume":"33","author":"Lv","year":"2015","journal-title":"Clin Exp Rheumatol"},{"key":"2022013117274921900_cvab032-B107","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1016\/j.autrev.2017.10.013","article-title":"The anti-inflammatory effects of statins on patients with rheumatoid arthritis: a systemic review and meta-analysis of 15 randomized controlled trials","volume":"17","author":"Li","year":"2018","journal-title":"Autoimmun Rev"},{"key":"2022013117274921900_cvab032-B108","doi-asserted-by":"crossref","first-page":"2603","DOI":"10.1002\/art.39774","article-title":"Statins and risk of rheumatoid arthritis: a nested case-control study","volume":"68","author":"Tascilar","year":"2016","journal-title":"Arthritis Rheumatol"},{"key":"2022013117274921900_cvab032-B109","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/j.atherosclerosis.2012.02.023","article-title":"Dual effects of statins therapy in systemic lupus erythematosus and SLE-related atherosclerosis: the potential role for regulatory T cells","volume":"222","author":"Tu","year":"2012","journal-title":"Atherosclerosis"},{"key":"2022013117274921900_cvab032-B110","doi-asserted-by":"crossref","first-page":"877","DOI":"10.1111\/bcp.12564","article-title":"Pleiotropic effects of statins on the treatment of chronic periodontitis\u2014a systematic review","volume":"79","author":"Estanislau","year":"2015","journal-title":"Br J Clin Pharmacol"},{"key":"2022013117274921900_cvab032-B111","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1155\/2019\/6367402","article-title":"Contribution of statins towards periodontal treatment: a review","volume":"2019","author":"Petit","year":"2019","journal-title":"Mediators Inflamm"},{"key":"2022013117274921900_cvab032-B112","doi-asserted-by":"crossref","first-page":"1860","DOI":"10.1016\/j.cgh.2018.11.002","article-title":"Statin use is associated with improved outcomes of patients with primary sclerosing cholangitis","volume":"17","author":"Stokkeland","year":"2019","journal-title":"Clin Gastroenterol Hepatol"},{"key":"2022013117274921900_cvab032-B113","doi-asserted-by":"crossref","first-page":"1416","DOI":"10.1038\/ajg.2016.233","article-title":"Statins associated with decreased risk of new onset inflammatory bowel disease","volume":"111","author":"Ungaro","year":"2016","journal-title":"Am J Gastroenterol"},{"key":"2022013117274921900_cvab032-B114","doi-asserted-by":"crossref","first-page":"5804","DOI":"10.1038\/s41598-018-24248-8","article-title":"Use of statins and the risk of dementia and mild cognitive impairment: a systematic review and meta-analysis","volume":"8","author":"Chu","year":"2018","journal-title":"Sci Rep"},{"key":"2022013117274921900_cvab032-B115","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1186\/s40035-018-0110-3","article-title":"The role of statins in both cognitive impairment and protection against dementia: a tale of two mechanisms","volume":"7","author":"Schultz","year":"2018","journal-title":"Transl Neurodegener"},{"key":"2022013117274921900_cvab032-B116","doi-asserted-by":"crossref","first-page":"690","DOI":"10.1016\/S0735-1097(03)00785-X","article-title":"Long-term statin use and psychological well-being","volume":"42","author":"Young-Xu","year":"2003","journal-title":"J Am Coll Cardiol"},{"key":"2022013117274921900_cvab032-B117","doi-asserted-by":"crossref","first-page":"484","DOI":"10.1002\/phar.2397","article-title":"Considerations for statin therapy in patients with COVID-19","volume":"40","author":"Dashti-Khavidaki","year":"2020","journal-title":"Pharmacotherapy"},{"key":"2022013117274921900_cvab032-B118","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1002\/ddr.21666","article-title":"COVID-19 treatment by repurposing drugs until the vaccine is in sight","volume":"81","author":"Phadke","year":"2020","journal-title":"Drug Dev Res"},{"key":"2022013117274921900_cvab032-B119","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1093\/ehjcvp\/pvaa042","article-title":"Statin therapy in COVID-19 infection","author":"Castiglione","year":"2020","journal-title":"Eur Heart J Cardiovasc Pharmacother"},{"key":"2022013117274921900_cvab032-B120","doi-asserted-by":"crossref","first-page":"1076","DOI":"10.1164\/rccm.201306-1017OC","article-title":"Statin exposure is associated with decreased asthma-related emergency department visits and oral corticosteroid use","volume":"188","author":"Tse","year":"2013","journal-title":"Am J Respir Crit Care Med"},{"key":"2022013117274921900_cvab032-B121","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1016\/j.addr.2018.06.005","article-title":"Repurposing of statins via inhalation to treat lung inflammatory conditions","volume":"133","author":"Bradbury","year":"2018","journal-title":"Adv Drug Deliv Rev"},{"key":"2022013117274921900_cvab032-B122","doi-asserted-by":"crossref","first-page":"490","DOI":"10.5114\/aoms.2020.94655","article-title":"Statins and the COVID-19 main protease: in silico evidence on direct interaction","volume":"16","author":"Reiner","year":"2020","journal-title":"AOMS"},{"key":"2022013117274921900_cvab032-B123","doi-asserted-by":"crossref","first-page":"1925","DOI":"10.1161\/CIRCULATIONAHA.111.028571","article-title":"Squalene synthase inhibitor lapaquistat acetate: could anything be better than statins?","volume":"123","author":"Liao","year":"2011","journal-title":"Circulation"},{"key":"2022013117274921900_cvab032-B124","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1177\/2047487319864671","article-title":"Bempedoic acid plus ezetimibe fixed-dose combination in patients with hypercholesterolemia and high CVD risk treated with maximally tolerated statin therapy","volume":"27","author":"Ballantyne","year":"2019","journal-title":"Eur J Prev Cardiol"},{"key":"2022013117274921900_cvab032-B125","doi-asserted-by":"crossref","first-page":"1022","DOI":"10.1056\/NEJMoa1803917","article-title":"Safety and efficacy of bempedoic acid to reduce LDL cholesterol","volume":"380","author":"Ray","year":"2019","journal-title":"N Engl J Med"},{"key":"2022013117274921900_cvab032-B126","doi-asserted-by":"crossref","first-page":"1780","DOI":"10.1001\/jama.2019.16585","article-title":"Effect of bempedoic acid vs placebo added to maximally tolerated statins on low-density lipoprotein cholesterol in patients at high risk for cardiovascular disease: the CLEAR Wisdom Randomized Clinical Trial","volume":"322","author":"Goldberg","year":"2019","journal-title":"JAMA"},{"key":"2022013117274921900_cvab032-B127","doi-asserted-by":"crossref","first-page":"758","DOI":"10.1016\/j.jacl.2015.08.006","article-title":"Efficacy and safety of alirocumab vs ezetimibe in statin-intolerant patients, with a statin rechallenge arm: the ODYSSEY ALTERNATIVE randomized trial","volume":"9","author":"Moriarty","year":"2015","journal-title":"J Clin Lipidol"},{"key":"2022013117274921900_cvab032-B128","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1161\/CIRCULATIONAHA.108.813311","article-title":"Evidence for statin pleiotropy in humans: differential effects of statins and ezetimibe on rho-associated coiled-coil containing protein kinase activity, endothelial function, and inflammation","volume":"119","author":"Liu","year":"2009","journal-title":"Circulation"},{"key":"2022013117274921900_cvab032-B129","doi-asserted-by":"crossref","first-page":"536","DOI":"10.1016\/j.bbrc.2015.09.065","article-title":"Skeletal muscle-specific HMG-CoA reductase knockout mice exhibit rhabdomyolysis: a model for statin-induced myopathy","volume":"466","author":"Osaki","year":"2015","journal-title":"Biochem Biophys Res Commun"},{"key":"2022013117274921900_cvab032-B130","doi-asserted-by":"crossref","first-page":"1824","DOI":"10.1161\/ATVBAHA.111.240754","article-title":"Liver-specific deletion of 3-hydroxy-3-methylglutaryl coenzyme A reductase causes hepatic steatosis and death","volume":"32","author":"Nagashima","year":"2012","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"2022013117274921900_cvab032-B131","doi-asserted-by":"crossref","first-page":"2590","DOI":"10.1161\/ATVBAHA.118.311664","article-title":"Myeloid HMG-CoA (3-hydroxy-3-methylglutaryl-coenzyme A) reductase determines atherosclerosis by modulating migration of macrophages","volume":"38","author":"Sakai","year":"2018","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"2022013117274921900_cvab032-B132","doi-asserted-by":"crossref","first-page":"42936","DOI":"10.1074\/jbc.M307228200","article-title":"Early embryonic lethality caused by targeted disruption of the 3-hydroxy-3-methylglutaryl-CoA reductase gene","volume":"278","author":"Ohashi","year":"2003","journal-title":"J Biol Chem"}],"container-title":["Cardiovascular Research"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/cardiovascres\/advance-article-pdf\/doi\/10.1093\/cvr\/cvab032\/36297372\/cvab032.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/cardiovascres\/article-pdf\/118\/2\/413\/42340736\/cvab032.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/cardiovascres\/article-pdf\/118\/2\/413\/42340736\/cvab032.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,20]],"date-time":"2023-10-20T03:25:49Z","timestamp":1697772349000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/cardiovascres\/article\/118\/2\/413\/6127170"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,2,3]]},"references-count":132,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2021,2,3]]},"published-print":{"date-parts":[[2022,1,29]]}},"URL":"https:\/\/doi.org\/10.1093\/cvr\/cvab032","relation":{},"ISSN":["0008-6363","1755-3245"],"issn-type":[{"value":"0008-6363","type":"print"},{"value":"1755-3245","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2022,2,1]]},"published":{"date-parts":[[2021,2,3]]}}}